FBLN2, FBLN3, and FBLN5 have been shown to regulate Notch (Baird et al., 2013), Insulin Growth Factor receptor (IGF1R) (Kim et al., 2014), EGFR signaling pathways, respectively, in glioma (Hu et al., 2009), lung (Yue et al., 2009; Kim et al., 2014; Wang et al., 2017), and pancreatic cancers (Camaj et al., 2009). Here, EGFR is linked to central nervous system cancer.